Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Theravance - THRX -- Ignore unavailable to you. Want to Upgrade?

To: bio_kruncher who wrote (41)	8/28/2006 1:36:10 PM
From: Biomaven	Respond to of 74

Many thanks bio kruncher - that all makes sense now. Peter

To: bio_kruncher who wrote (41)	8/28/2006 2:08:11 PM
From: DewDiligence_on_SI	Respond to of 74

In these studies, non-inferiority was needed to claim effectiveness. If the test of superiority in MRSA was conditional on first achieving non-inferiority overall then no alpha adjustment would be needed. That’s the key to not exhausting additional alpha for the dual endpoints and it applies to many trials even where the superiority claim is based on the full ITT population; i.e., these trial protocols require a finding of non-inferiority in order for a finding of superiority to have force, which is consistent with the Hochberg correction: investorshub.com However, a trial protocol specified in an SPA is not required to use the Hochberg correction (as above), and hence there could be some cases where there are separate alphas for the two endpoints.